CXC Chemokine Receptor 4 Antagonist class drugs
1 result
Xolremdi (mavorixafor)
(mavorixafor)X4 Pharmaceuticals, Inc.
Usage: XOLREMDI is indicated for patients aged 12 and older with WHIM syndrome to increase circulating mature neutrophils and lymphocytes, addressing warts, hypogammaglobulinemia, infections, and myelokathexis.